Hyperuricemia – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Hyperuricemia – Pipeline Review, H2 2016’, provides an overview of the Hyperuricemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hyperuricemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hyperuricemia

The report reviews pipeline therapeutics for Hyperuricemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hyperuricemia therapeutics and enlists all their major and minor projects

The report assesses Hyperuricemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hyperuricemia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hyperuricemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hyperuricemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allena Pharmaceuticals, Inc.

AstraZeneca Plc

CymaBay Therapeutics, Inc.

Jiangsu Hengrui Medicine Co., Ltd.

Nippon Chemiphar Co., Ltd.

Nobelpharma Co., Ltd.

Polaris Pharmaceuticals, Inc.

Teijin Pharma Limited

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Hyperuricemia Overview 8

Therapeutics Development 9

Pipeline Products for Hyperuricemia - Overview 9

Pipeline Products for Hyperuricemia - Comparative Analysis 10

Hyperuricemia - Therapeutics under Development by Companies 11

Hyperuricemia - Therapeutics under Investigation by Universities/Institutes 12

Hyperuricemia - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Hyperuricemia - Products under Development by Companies 16

Hyperuricemia - Products under Investigation by Universities/Institutes 17

Hyperuricemia - Companies Involved in Therapeutics Development 18

Allena Pharmaceuticals, Inc. 18

AstraZeneca Plc 19

CymaBay Therapeutics, Inc. 20

Jiangsu Hengrui Medicine Co., Ltd. 21

Nippon Chemiphar Co., Ltd. 22

Nobelpharma Co., Ltd. 23

Polaris Pharmaceuticals, Inc. 24

Teijin Pharma Limited 25

Hyperuricemia - Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Combination Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

(allopurinol + lesinurad) - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

ALLN-346 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

arhalofenate - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

febuxostat - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

JPH-367 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

NC-2500 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

NC-2700 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

pegadricase - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Pyruvic acid - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

SHR-4640 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

TMX-049 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

verinurad - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

XEN-102 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Hyperuricemia - Dormant Projects 58

Hyperuricemia - Discontinued Products 59

Hyperuricemia - Product Development Milestones 60

Featured News & Press Releases 60

Jun 15, 2016: Scottish Medicines Consortium Accepts Adenuric (Febuxostat) for the Prevention and Treatment of Hyperuricaemia and Predicts Savings for NHS Scotland 60

May 23, 2016: Teijin Pharma’s Feburic (Febuxostat) Approved as Indication for Cancer Chemotherapy-Induced Hyperuricemia 61

Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6 - 11 61

Jun 30, 2015: New Indication for Teijin Pharma’s Febuxostat in Europe 62

Jan 12, 2015: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat 63

Nov 01, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Uloric 64

Apr 11, 2012: Teijin Pharma And Menarini Sign Distribution Agreement For Marketing Of Febuxostat 64

Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat 65

Jul 28, 2011: Teijin Pharma Launches Febuxostat In Korea 66

May 13, 2011: Teijin Pharma To Launch FEBURIC In Japan 66

Apr 18, 2011: Teijin Pharma Expands Global Market For TMX-67 67

Jan 21, 2011: Teijin Pharma Receives Approval Of TMX-67 For Treating Hyperuricemia In Japan 67

Oct 27, 2010: Teijin Pharma Launches TMX-67 In Canada 68

Mar 09, 2010: Menarini Launches ADENURIC (Febuxostat) In Europe 68

Mar 05, 2010: Launch by Menarini and Ipsen of Adenuric (febuxostat) in France for the treatment of chronic hyperuricemia in gout 68

Appendix 70

Methodology 70

Coverage 70

Secondary Research 70

Primary Research 70

Expert Panel Validation 70

Contact Us 70

Disclaimer 71

List of Tables

List of Tables

Number of Products under Development for Hyperuricemia, H2 2016 9

Number of Products under Development for Hyperuricemia – Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Development, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Hyperuricemia – Pipeline by Allena Pharmaceuticals, Inc., H2 2016 18

Hyperuricemia – Pipeline by AstraZeneca Plc, H2 2016 19

Hyperuricemia – Pipeline by CymaBay Therapeutics, Inc., H2 2016 20

Hyperuricemia – Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 21

Hyperuricemia – Pipeline by Nippon Chemiphar Co., Ltd., H2 2016 22

Hyperuricemia – Pipeline by Nobelpharma Co., Ltd., H2 2016 23

Hyperuricemia – Pipeline by Polaris Pharmaceuticals, Inc., H2 2016 24

Hyperuricemia – Pipeline by Teijin Pharma Limited, H2 2016 25

Assessment by Monotherapy Products, H2 2016 26

Assessment by Combination Products, H2 2016 27

Number of Products by Stage and Target, H2 2016 29

Number of Products by Stage and Mechanism of Action, H2 2016 31

Number of Products by Stage and Route of Administration, H2 2016 33

Number of Products by Stage and Molecule Type, H2 2016 35

Hyperuricemia – Dormant Projects, H2 2016 58

Hyperuricemia – Discontinued Products, H2 2016 59

List of Figures

List of Figures

Number of Products under Development for Hyperuricemia, H2 2016 9

Number of Products under Development for Hyperuricemia – Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy Products, H2 2016 26

Number of Products by Targets, H2 2016 28

Number of Products by Stage and Targets, H2 2016 28

Number of Products by Mechanism of Actions, H2 2016 30

Number of Products by Stage and Mechanism of Actions, H2 2016 30

Number of Products by Routes of Administration, H2 2016 32

Number of Products by Stage and Routes of Administration, H2 2016 32

Number of Products by Molecule Types, H2 2016 34

Number of Products by Stage and Molecule Types, H2 2016 34

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports